Mami Morita

Natori-shi, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.

Journal: Cancer science

Published: May 06, 2026

Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.

Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.

Journal: Anticancer research

Published: August 18, 2023

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety.

Journal: Biomedicines

Published: August 10, 2023

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma.

Journal: Nature communications

Published: April 18, 2023

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).

Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).

Journal: International journal of clinical oncology

Published: March 08, 2022

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).

Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).

Journal: International journal of clinical oncology

Published: June 16, 2021

Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402.

Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402.

Journal: Thoracic cancer

Published: June 02, 2021

Dietary intervention as a therapeutic for cancer.

Dietary intervention as a therapeutic for cancer.

Journal: Cancer science

Published: November 03, 2020

Comparison of the ischemic and non-ischemic lung cancer metabolome reveals hyper activity of the TCA cycle and autophagy.

Comparison of the ischemic and non-ischemic lung cancer metabolome reveals hyper activity of the TCA cycle and autophagy.

Journal: Biochemical and biophysical research communications

Published: June 30, 2020

Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.

Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.

Journal: FEBS letters

Published: September 03, 2019

A metabolic vulnerability of small-cell lung cancer.

A metabolic vulnerability of small-cell lung cancer.

Journal: Oncotarget

Published: July 27, 2018

Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model.

Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model.

Journal: Molecular & cellular oncology

Published: April 11, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026